Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ribociclib + endocrine therapy
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
Ribociclib is an oral small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), developed as a targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. It works by blocking CDK4/6 proteins, which are essential for cell cycle progression in cancer cells, thereby slowing or stopping tumor growth. Ribociclib is used in combination with endocrine therapies such as aromatase inhibitors (e.g., letrozole) or fulvestrant to treat advanced or metastatic HR+/HER2- breast cancer in adults. In premenopausal women, it may be combined with a GnRH agonist to suppress ovarian function[1][3][4][5][8]. The primary indication is advanced or metastatic HR+/HER2- breast cancer; it has also been studied for early-stage disease at high risk of recurrence[1][2].
- Brand names
- Kisqali
- Other names
- ribociclib + ETribociclib succinate and letrozole
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6/CCND3 (Cyclin-dependent kinase 6/Cyclin D3 complex)
Beyond the preview
Go deeper on ribociclib + endocrine therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ribociclib + endocrine therapy.